The Society for Immunotherapy of Cancer, with support from Merck, is providing funding for cancer immunotherapy research through the SITC-Merck Cancer Immunotherapy Clinical Fellowship
President Barack Obama and several members of Congress announced a slew of initiatives this week aimed at eliminating the effects of sequestration for the government, and for medical research by providing increases for NIH and other federal agencies.
Robert Califf was named FDA Deputy Commissioner for Medical Products and Tobacco, a de facto No. 2 post at the agency.
The trial stemming from Duke University's clinical trials of a fraudulent genomic technology has been delayed, most likely until September.
The House Committee on Energy and Commerce Jan. 27 released a draft version of a massive bill that seeks to streamline the pathways of innovation in medicine.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. If approved in the EU, ruxolitinib could provide the first targeted treatment option for these patients.
Ventana Medical Systems Inc., a member of the Roche Group, announced its FDA submission for premarket approval of the VENTANA ALK (D5F3) CDx Assay.
Palmetto GBA, a national contractor that administers Medicare benefits, issued a positive coverage policy through the MolDX Program for the Decipher prostate cancer classifier developed by GenomeDx Biosciences.
PICADOR acquired world rights to a debut novel by Paul Goldberg, editor and publisher of The Cancer Letter. Set in Moscow in late February and early March of 1953, the novel is only in part about medicine. It's expected to be published in early 2016.
ROYAL PHILIPS will analyze pathology samples using advanced image analysis algorithms from Indica Labs Inc. as part of its Digital Pathology Solutions offerings.
